ISA Pharmaceuticals is pioneering the development of Synthetic Long Peptides (SLP®) as targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections. ISA’s SLP® technology can be widely applied against a multitude of antigens, from antigens shared in large groups of patients or, ultimately, selected from an individual patient.
In addition, ISA’s AMPLIVANT® technology establishes a new generation of chemically defined and potent SLP® immunotherapeutics, potentially strengthening targeted immune responses.